Sanofi, the French healthcare giant, has extended its agreement with Alliance Pharma for the Chippenham-based specialist pharmaceutical firm to distribute its ImmuCyst cancer drug in the UK and Ireland for a further seven years.
Sales of ImmuCyst, a treatment for non-muscle-invasive bladder cancer, in the year to April 30 in the UK and Ireland were £3.7m. It has been distributed by Alliance's Cambridge Laboratories business since Alliance acquired the trade and certain assets of Cambridge in February last year. The agreement renewal, by Sanofi's vaccines division Sanofi Pasteur triggers payment by Alliance of up to £2.1m deferred cash consideration for Cambridge.
Chief executive John Dawson said:"I am delighted that Sanofi Pasteur has demonstrated its continued confidence in the work of the Cambridge Laboratories business unit. We will aim to reward that confidence with further success from this cornerstone of our oncology portfolio during the coming years."
